No correlation was found between the expression of these three markers and patient survival [241], but others have shown that the combined evaluation of CD133, CD166 and CD44 could be used to identify high and low survival among stage I and II CRC patients [242]. This evidence concerns the gene PROM1 and colorectal carcinoma.